新复合纤维蛋白胶可注射性磷酸钙人工骨的理学特性

目的:检测纤维蛋白胶复合β-磷酸三钙/磷酸二氢钙复合人工骨材料的物理学性能,评价纤维蛋白胶对β-磷酸三钙/磷酸二氢钙骨水泥性能的影响,以及其作为注射型复合人工骨用于修复骨缺损的可行性。方法:实验于2006-12/2007-06在南方医科大学珠江医院中心实验室和华南理工大学生物材料实验室完成。①材料:β-磷酸三钙由上海瑞邦生物材料有限公司提供,磷酸二氢钙为东泰化工赠,纤维蛋白胶购自广州倍绣生物技术有限公司。②复合材料制备:将β-磷酸三钙/磷酸二氢钙骨水泥按3∶1的比例充分混合后,与纤维蛋白胶按凝固后的体积2∶1体积比混合,制成复合人工骨材料。③观察指标:测定复合材料的凝固时间,抗压强度,抗稀散性能,并用扫描电镜观察其煅烧前后的显微结构特征,以未加纤维蛋白胶的磷酸钙水泥为对照(CPC组)。结果:复合人工骨材料的平均初凝时间长于CPC组(P<0.004),终凝时间在初凝时间后2～4 min;复合材料的抗压强度为(14.72±1.81)MPa。复合材料较CPC组有良好的抗稀散性能,扫描电镜发现,纤维蛋白胶贯穿于磷酸钙水泥晶体间,并将磷酸钙水泥晶体紧密连接。煅烧后复合材料的孔径有增大,空隙率为57.28%,并且微孔之间有空隙互相贯通。结论:该骨水泥复合材料凝固时间符合临床操作的需要;抗压强度达到松质骨强度的要求;煅烧后磷酸钙水泥的空隙率明显提高,有利于材料的降解。     

Practical guidelines for process validation and process control of white cell-reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT)

Background: The increased use of white (WBC)-reduced blood components has prompted many institutions to develop quality assurance programs directed to such component preparation processes. For consistent preparation of WBC-reduced blood components that meet clinical needs as well as national standards, a program of process validation and control should be instituted. This involves controlling key factors that affect WBC reduction as well as periodic monitoring of the residual cellular content of components. Practical guidelines for the implementation of such a program are provided. Study Design and Methods: A program involving three phases of monitoring was developed by individuals belonging to an international working party of the International Society of Blood Transfusion. Results: The first phase, process validation, evaluates a minimum of 20 consecutive units (a minimum of 60 units when nonparametric measurements are used) to document the successful local implementation of a new or substantially modified process. Ongoing process control employing Levey-Jennings type control charts is used to demonstrate that the process remains stable over time. Process capability assessment and conformance with standards are evaluated once residual WBCs are counted in a sufficient number of units. This enables a facility to claim with a specified degree of confidence that a stated proportion of WBC-reduced units will meet national standards. Two approaches to determine the number of units that should be selected for counting are presented. The first approach considers units as either acceptable or not acceptable and assumes that the distribution of failed (or nonconforming) units approximates the Poisson distribution. The second approach takes into consideration the observed WBC content of the tested units, with the assumption that the residual WBC content in WBC-reduced components follows a lognormal distribution. A method to assess the lognormal distribution of residual WBCs is presented. Specific tables based on each of these approaches are provided to guide the reader in the design of a program that will verify conformance with any national standard at specific confidence levels. The approach can be generalized to other process control applications. Conclusion: Guidelines are presented for process validation, process control, and assessment of conformance in the production of WBC-reduced blood components. Policy makers retain the responsibility to establish, on the basis of the expected use of WBC- reduced components, requirements for the frequency of testing and for the proportion of prepared units that are expected with a stated degree of confidence to meet the standards. Facilities preparing WBC-reduced components can monitor key factors that influence the preparation of WBC-reduced blood, can periodically assess their conformance with the standards, and can intervene to correct adverse changes in the process. This approach can be used to ensure the consistent quality of WBC- reduced blood components.     

Microdroplet fluorochromatic assay for the enumeration of white cells (WBCs) in WBC-reduced blood components: validation and application for evaluating newly developed WBC-reduction filters

BACKGROUND: Sensitive and accurate counting methods are required to assess the residual white cells (WBCs) in WBC-reduced blood components. The Nageotte hemocytometer, widely used for this purpose, is cumbersome, and its efficacy is dependent upon the skill of the operator. The performance of a simple fluorochromatic assay using tissue-typing microdroplet trays is presented here. STUDY DESIGN AND METHODS: Undiluted samples of blood components were mixed with a fluorochromatic dye in trays. WBCs were counted under an epifluorescence microscope. The accuracy and sensitivity of this method were compared with those of the reference Nageotte hemocytometer method by using serial dilution of samples of platelets and red cells containing known concentrations of WBCs and by calculating the standard curves. The Nageotte hemocytometer and the microdroplet fluorochromatic assay (MFA) were also compared in terms of count correlation and reproducibility in 320 paired counts of plateletpheresis samples. MFA was used to evaluate a newly developed WBC-reduction red cell filter. RESULTS: The MFA for platelets and red cells was linear to 0.1 and 0.03 WBCs per microL, respectively. The linear regression line of log10 MFA versus log10 Nageotte method had a slope of 0.963, intercept of -0.04, and r2 of 0.968. The Nageotte method gave an estimation of WBC content 12 to 20 percent greater than that of the MFA. The MFA, with a larger neat sample volume, showed precision comparable to that of the Nageotte method. The filters demonstrated a median WBC reduction of 4.8 log10. CONCLUSION: The MFA is a sensitive and accurate method for quality control processes to assess the residual WBCs in WBC-reduced blood components.     

Sampling errors and the precision associated with counting very low numbers of white cells in blood components

Attention to the accurate and precise measurement of the white cell (WBC) content of transfused products has risen in response to awareness of the potential benefits of WBC-depleted components and the development of technical capabilities to produce these components. The techniques thus far reported have focused on the reliability of detecting a WBC, provided it is present in the test system. The likelihood of selecting a WBC from the product of interest for counting in the analytical system--that is, the sampling error--must also be considered. The occurrence of a WBC in a WBC-depleted component is a rare event and may be modeled with the binomial or the Poisson distribution. Several assay techniques were analyzed by using these distribution models to determine the confidence intervals of the WBC content. The 95-percent confidence intervals spanned more than 2 logs10 for some methods at 3 x 10(5) WBCs per product. It is concluded that the reporting of WBC content for research provides not only the estimate of the mean but also a confidence interval for this estimate. Quality control procedures should be designed to verify that the WBC content is less than the targeted amount and should provide an associated statement of confidence.     

血管内皮生长因子与白细胞介素12在急性白血病不同时期血清中的变化

目的:由于造血干/祖细胞发生基因突变,子代细胞增殖失控等导致的恶性血液病。血管内皮生长因子和白细胞介素12参与这一发生发展过程,检测不同时期其在急性白血病患者静脉血中的水平,有利于认知与血管新生及体液免疫的相关性。方法:随机选择2005-06/2006-04在吉林市中心医院住院的急性白血病患者25例,均经FAB分型或免疫学分型确诊,患者知情同意,并经医院伦理委员会批准。将患者分为:①初诊未治组10例。②复发组5例。③完全缓解组10例。并设9名健康查体者为正常对照。应用定量酶联免疫吸附实验测定受试者血清中血管内皮生长因子和白细胞介素12的水平,在评定白细胞介素12水平时,将初诊未治组与复发组合并为初诊复发组:①两组的发病机制相似。②两组病例数较少,单独观察没有统计学意义。结果:25例患者和9名健康对照者均进入结果分析。①初诊未治组血管内皮生长因子含量高于完全缓解组及正常对照组(P均<0.05)。②正常对照组白细胞介素12水平与初诊复发组、完全缓解组之间差异均具有显著性意义(P均<0.05)。③正常对照组血管内皮生长因子含量与白细胞介素12之间存在负相关(r=-0.9644P<0.05)。④初诊复发组、完全缓解组血管内皮生长因子和白细胞介素12含量之间均无相关性(r=-0.0883,-0.3593,P均>0.05)。结论:急性白血病患者血清中血管内皮生长因子和白细胞介素12含量与临床病情变化有关,可以作为诊断和预测急性白血病发生和复发的指标。     

A study of confidential unit exclusion

The effectiveness of the confidential unit exclusion (CUE) procedure recommended by the Food and Drug Administration has been questioned by the blood banking community. The purpose of this study was to determine whether donors were informing the blood center correctly regarding the disposition (transfuse or do not transfuse) of their donated blood. A letter explaining the confidential study and requesting permission to send the participant a questionnaire noting his or her self-exclusion choice was mailed to 230 donors who had chosen transfuse and 276 donors who had chosen do not transfuse. After consent was obtained, participants were sent a second packet and asked to indicate whether they had chosen correctly and, if not, to identify reasons for that incorrect choice. A seven-word terminology quiz made up of words from the CUE form was also enclosed. All participants who had chosen transfuse indicated that this was the correct choice. Approximately 50 percent of those who had chosen do not transfuse indicated that this was an incorrect choice; the most common reason was that "I was not paying attention." The most frequently misunderstood term was "confidential." Donors who chose do not transfuse had a significantly higher rate of error on the terminology quiz (p less than 0.01) than did those who chose transfuse.     

Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency

We treated patients with idiopathic membranous nephropathy (iMGN) and renal insufficiency, using: (i) (n = 15) monthly cycles of steroids (1 g methyl-prednisolone i.v. on three consecutive days, followed by oral prednisone 0.5 mg/kg/day months 1, 3 and 5) and chlorambucil (0.15 mg/kg/day months 2, 4 and 6); or (ii) (n = 17) oral cyclophosphamide (1.5-2.0 mg/kg/day for 1 year) and steroids in a comparable dose. The groups were comparable in age, renal function and levels of proteinuria. During the 6 months preceding treatment, serum creatinine levels increased from 148 +/- 50 to 219 +/- 73 mumol/l in the chlorambucil group and from 164 +/- 86 to 274 +/- 126 mumol/l in the cyclophosphamide group. Median (range) follow-ups were: chlorambucil 38 months (8-71); cyclophosphamide 26 months (5-68) (NS). Renal function improved in both groups, but the improvement was short-lived in the chlorambucil group; 12 months after starting treatment, mean serum creatinine was 6.3 mumol/l lower in the chlorambucil group and 121 mumol/l lower in the cyclophosphamide group (p < 0.01). Four chlorambucil-treated patients developed ESRD, and five needed a second course of therapy, whereas only one cyclophosphamide-treated patient developed ESRD (p < 0.05). Remissions of proteinuria occurred more frequently after cyclophosphamide treatment (15/17 vs. 5/15; p < 0.01). Side-effects necessitated interruption of treatment in six patients on cyclophosphamide and in 11 on chlorambucil (p < 0.05). In our patients, oral cyclophosphamide was better tolerated than oral chlorambucil. The suggested greater efficacy of the oral cyclophosphamide regimen needs to be ascertained by longer follow-up.      

成纤维细胞生长因子Ⅱ型受体功能获得型点突变影响小鼠颅底软骨发育

目的:对比野生型小鼠和成纤维细胞生长因子Ⅱ型受体(fibroblast growth factor receptor2,fgfr2)基因S252W突变型小鼠颅底软骨的生长发育情况,探讨fgfr2功能持续增强对小鼠颅底软骨发育的影响。方法:实验于2004-03/2005-04在解放军第三军医大学大坪医院野战外科研究所创伤中心实验室,创伤、烧伤与复合伤国家重点实验室完成。①fgfr2 小鼠和C57BL/6J小鼠交配后取F1代,利用聚合酶链反应方法进行fgfr2突变型小鼠基因型的鉴定,得到野生型和fgfr2受体功能获得型点突变型两组小鼠。②标本取材及处理:分别在两组实验动物中,取胚胎期16d(E16)、胚胎期17d(E17)、新生2d(P2)、新生8d(P8)的小鼠的颅底作为标本。一部分体积分数为0.75的乙醇溶液固定。另一部分标本行40g/L多聚甲醛固定,150g/L乙二胺四乙酸溶液脱钙,常规石蜡包埋、切片。③阿尔辛-茜素红骨架染色显示颅底整体骨骼的发育情况。软骨组织染为蓝色,骨组织染为红色。④脱钙骨切片后进行苏木精-伊红染色。未脱钙骨切片后进行Calcein染色,荧光显微镜下观察钙化组织的情况。⑤使用地高辛RNA标记试剂盒按照产品说明制备Col 10(Collagen 10)地高辛标记的互补RNA探针,对颅底软骨联结进行检测软骨分化标志基因表达情况的原位杂交。⑥组织切片染色结果使用SPOT Advanced软件进行数码拍摄。结果:①实验小鼠颅底发育的大体情况:fgfr2受体功能获得型点突变小鼠从胚胎后期开始就表现出短颅现象。②阿尔辛蓝-茜素红骨架染色、Calcein染色和苏木精-伊红染色显示,fgfr2受体功能获得型点突变小鼠出生后颅底软骨联结没有出现提前融合的现象,但是颅底软骨生长发育差,软骨细胞增生区、肥大区缩短。突变小鼠的颅底软骨发育障碍导致颅底骨组织的生长发育也出现障碍。③原位杂交:Col10在野生型和突变型小鼠颅底软骨的表达部位未见明显差异,但是这个软骨细胞分化标志基因的表达强度降低。结论:fgfr2 S252W点突变能够引起小鼠颅底软骨联结处的软骨细胞发育异常,导致颅底骨骼发育畸形。fgfr2可能具有调控软骨细胞系发育的功能,从而可能在骨骼发育、骨折修复等方面发挥重要作用。     

Progress in laparoscopic anatomy research: A review of the Chinese literature

The development of laparoscopic surgery has generated the new field of study, laparoscopic anatomy. This article reviews the reported literature on laparoscopic anatomy and explores how it has evolved along with advances in abdominal surgery. In addition, the principal concerns in current laparoscopic anatomy research are discussed, including: (1) types of special adjacent anatomical structures; and (2) special surgical planes and anatomical landmarks. Understanding of systematic laparoscopic anatomy can pr...